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Abstract
Background: Bergapten (5-methoxypsoralen), a natural psoralen derivative present in many fruits and vegetables,
has shown antitumoral effects in a variety of cell types. In this study, it has been addressed how Bergapten in
breast cancer cells induces autophagic process.
Results: In MCF7 and ZR-75 breast cancer cells Bergapten exhibited anti-survival response by inducing the
autophagic process increasing Beclin1, PI3KIII, UVRAG, AMBRA expression and conversion of LC3-I to LC3-II. LC3-GFP,
Acridine orange assay and transmission electron microscopy even confirmed the increased autophagosome formations
in treated cells. Bergapten-induced autophagy is dependent by PTEN up-regulation, since silencing this gene, the
induction of Beclin1 and the p-AKT/p-mTOR signal down-regulation were reversed. PTEN is transcriptionally regulated by
Bergapten through the involvement of p38MAPK/NF-Y, as evidenced by the use of p38MAPK inhibitor SB203580,
site-direct mutagenesis of NF-Y element and NF-Y siRNA. Furthermore NF-Y knockdown prevented Bergapten-induced
acid vesicular organelle accumulations (AVOs), strengthening the role of this element in mediating autophagy.
Conclusions: Our data indicate PTEN as a key target of Bergapten action in breast cancer cells for the induction of
autophagy. These findings add further details on the mechanism of action of Bergapten, therefore suggesting that
phytochemical compounds may be implemented in the novel strategies for breast cancer treatment.
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Background
Breast cancer is the most frequent malignant neoplasm of
female in Europe and North America and breast cancero-
genesis is still not fully recognized, due to many risk fac-
tors acting in a dynamic bio-molecular context. Besides,
prognostic factors commonly used for the follow up of pa-
tients evidence an incomplete picture of the breast tumor
biology [1].
The oncosuppressor gene PTEN (Phosphatase tensin
homologue deleted from chromosome 10) is often mutated
in hormone-related tumors among women, including
breast [2] and PTEN expression correlates negatively with
neoplasm advancement grade [3]. PTEN codes protein/
lipid phosphatase governing phosphatidylinositol 3-kinase
(PI3K) signaling thus contributing to the control of the
proliferation, differentiation and apoptotic process [4].
PTEN has also been shown to mediate autophagy in mam-
malian cells through its lipid phosphatase activity which
antagonizes the inhibitory effect of the PI3K/AKT pathway
on the autophagic sequestration that involves type III PI3-
kinase [5].
The substantial evidence that the progression of breast
cancer can be influenced by PI3K/AKT/mTOR, suggests
the use of specific inhibitors as component of therapeutic
portfolio that could be able to increase the expression of
oncosuppressor PTEN.
In recent years, many naturally occurring compounds,
sometimes present in the diet have gained considerable
* Correspondence: saveria.aquila@libero.it; sebastiano.ando@unical.it;
mamissina@yahoo.it
†Equal contributors
1Department of Pharmacy, Health and Nutritional Sciences, University of
Calabria, 87036 Arcavacata di Rende, Cosenza, Italy
Full list of author information is available at the end of the article
© 2015 De Amicis et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
De Amicis et al. Molecular Cancer  (2015) 14:130 
DOI 10.1186/s12943-015-0403-4
Fig. 1 (See legend on next page.)
De Amicis et al. Molecular Cancer  (2015) 14:130 Page 2 of 12
attention as antitumor agents [6, 7]. In this regard
cumarine-derivate compound 5-methoxypsoralen (Bergap-
ten, Bg) has been shown to be antiproliferative and protect-
ive against various types of breast cancer cells [8, 9],
although limited information of molecular mechanism of
action is still available.
In particular, photo-activation of psoralen with UVA ir-
radiation, used in the treatment of proliferative skin disor-
ders, exerts antitumor effects in models of human breast
cancer that overexpress the ErbB2 receptor tyrosine kinase
oncogene, through a mechanism mediated by inhibition of
ErbB2 signaling [10]. Furthermore, we recently reported
that Bg, independently by its photo-activation, generates
membrane signaling pathways able to address apoptotic re-
sponses in breast cancer cells [9]. Besides, the Bg in
Tamoxifen-sensitive and Tamoxifen-resistant breast cancer
cells can act as estrogen receptor alpha down-regulator,
through a process involving the SMAD4 protein [8].
In the present study we provide evidence that Bg
evokes an autophagic phenotype associated with an anti-
survival response in breast cancer cells. These effects are
mediated by the up-regulation of PTEN expression due
to the activation of p38MAPK/NF-Y signaling.
Results
Bergapten upregulates PTEN expression and PTEN gene
promoter activity in MCF-7 and ZR-75 breast cancer cells
The PI3K is one of the most important pathway in cancer
cells for the integration of different functions, including
cellular metabolism, differentiation, and survival. We have
previously reported [11] that Bg was able to decrease the
PI3K activity, thus addressing apoptotic responses in
breast cancer cells. Based on these promising initial data,
we investigated if the drug was capable to influence the
PI3K inhibitor PTEN and its downstream effector Akt.
As shown in the Fig. 1, Bg treatment, from 6 to 16 h (h),
induces a significant increase of PTEN expression in
terms of protein (Fig. 1a, b) and mRNA content (Fig. 1c)
in both MCF-7 and ZR-75 cells. As presumed, pAkt, AKT
and p-mTOR, m-TOR expression levels were reduced by
Bg treatment and this effect was specifically mediated by
PTEN. Indeed, addition of a PTEN-targeting siRNA which
resulted in reduction of the correspondent protein levels
(Fig. 1b), clearly counteracted the Bg -dependent down-
regulation, addressing the involvement of the oncosup-
pressor protein in mediating Bg effects.
To further investigate the molecular basis for regulation
of PTEN gene expression by Bg, we transfected the full
length of the PTEN promoter gene spanning from −2927
to −160 bp (pGL3-2768) previously described [12, 13] into
MCF-7 and ZR-75 cells. Interestingly, the results in Fig. 2a
right panel indicate that 20 μM Bg significantly trans-
activated the pGL3-2768 construct in both cell types.
In order to identify the region of PTEN promoter re-
sponsible for Bg –induced transactivation we analyzed the
activity of a series of PTEN promoter deleted constructs
(Fig. 2a, left panel) previously described as an useful tool to
study the regulation of PTEN expression [12, 13]. As re-
vealed in Fig. 2a the promoter transactivation upon Bg was
observed only in the deleted construct pGl3-612 indicating
that the region between −1398 to −1118 bp was necessary
for the up-regulation of PTEN promoter activity produced
by Bg stimulation. Sequence analysis, showed that this re-
gion contains DNA motif able to bind NF-Y, that accounts
for promoter responsiveness to Bg [9]. Since NF-Y tran-
scription factor is a potential effector of Bg action [9]
which induces p38MAPK activation as we observed in
Additional file 1: Figure S1A, we wondered whether PTEN
up-regulation, might be dependent of this phosphorylative
pathway. In MCF-7 cells, pre-treated for 2 h with the
p38MAPK inhibitor SB203580 (10 μM), known to block
the kinase activities of p38 isoforms, the Bg-induced
up-regulation of PTEN mRNA (Fig. 1c), protein
levels (Additional file 1: Figure S1B) and gene pro-
moter activity (Fig. 2a) were abrogated.
To further assess NF-Y involvement in the Bg
-dependent induction of PTEN gene activity, we per-
formed site directed mutagenesis to alter NF-Y motif.
As shown in Fig. 2b, the activity of the mutated
construct was unaffected by Bg treatment. Besides
(See figure on previous page.)
Fig. 1 Bergapten-regulates PTEN protein and mRNA levels in breast cancer cells. a Western blot analysis of PTEN, p-AKT and AKT in MCF-7 and
ZR-75 breast cancer cells treated with vehicle (−) or Bg 20 μM or Bg 50 μM at different times as indicated. β-actin was used as loading control.
Autoradiographs show the results of one representative experiment. Columns, are mean of three independent experiments in which band
intensities were evaluated in terms of optical density arbitrary units and expressed as fold change over vehicle, which was assumed to be 1; bars,
SD;* P < 0.05 vs 6 h vehicle. ^ P < 0.05 vs 10 h vehicle. ** P < 0.05 vs 16 h vehicle. b Western blot analysis of PTEN, p-AKT, AKT, p-mTOR and mTOR
in MCF-7 cells transfected with non specific (NS) or targeted against PTEN siRNA treated with vehicle (−) or Bg 20 μM or Bg 50 μM for 16 h.
Autoradiographs show the results of one representative experiment. Columns, are mean of three independent experiments in which band
intensities were evaluated in terms of optical density arbitrary units and expressed as fold over vehicle, which was assumed to be 1; bars, SD;* P
< 0.05 vs NS siRNA vehicle. ^ P < 0.05 vs NS siRNA Bg 20 μM. ** P < 0.05 vs NS siRNA Bg 50 μM. c Real-time PCR assay of PTEN mRNA expression
in MCF-7 and ZR-75 cells treated with vehicle (−), Bg 20 μM, Bg 50 μM (left panel) and/or p38MAPK inhibitor SB203580 (SB 10 μM) (right panel).
18S rRNA was determined as control. Columns are the mean of three independent experiments each in triplicate; bars, SD; *P < 0.05 vs vehicle
treated cells. ** P < 0.05 vs Bg 20 μM
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specific NF-Y siRNA substantially counteracted Bg ef-
fects on PTEN expression (Fig. 2c) addressing how
this factor is fundamental for Bg action.
Bergapten-action in breast cancer cells induces the
autophagic process
Since PTEN through inhibition of PI3K/Akt pathway
modulates autophagy, we next investigated the Bg -action
on the expression of the specific autophagy master regula-
tor Beclin1, having a prevalent role in the early phases of
the process. As shown in Fig. 3a Bg treatment increased
Beclin1 levels and this effect was specifically mediated by
PTEN, indeed in MCF-7 cells transfected with a specific
PTEN-siRNA, Bg was no longer able to induce the up-
regulation of Beclin1 expression. In both breast cancer cell
types, Bg induced the expression of other strictly related
proteins such as PI3KIII, UVRAG, and AMBRA which co-
operate to the autophagosome formation (Fig. 3b).
When autophagy is activated, PI3KIII causes lipidation
of LC3-I (microtubule-associated protein 1 light chain 3)
Fig. 2 Bergapten transactivates PTEN promoter gene in MCF-7 and ZR-75 cells. a Left panel: schematic representation of deletion fragments of
the PTEN gene promoter. Right panel: constructs depicted were transiently transfected in MCF-7 and ZR-75 cells as indicated, treated with vehicle
(−), Bg 20 μM or Bg 20 μM+ SB203580 (10 μM). b Site-directed mutagenesis of the NF-Y site. pGL3-612 and pGL3-612 Mut promoter constructs
were transfected into MCF-7 cells, and promoter activity was assessed in the absence or presence of Bg 20 μM treatment. Columns are mean of
three independent experiments and expressed as fold change over vehicle, which was assumed to be 1; bars, SD; *P < 0.05 vs vehicle. ** P < 0.05
vs pGL3-612 Bg 20 μM. c Western blot analysis of PTEN and NF-Y in MCF-7 cells transfected with non specific (NS) or targeted against NF-Y siRNA
treated with vehicle (−) or Bg 20 μM for 16 h. β-actin was used as loading control. Autoradiographs show the results of one representative
experiment out of three. Columns, are mean of three independent experiments in which band intensities were evaluated in terms of optical
density arbitrary units and expressed as fold over vehicle, which was assumed to be 1; bars, SD;* P < 0.05 vs NS siRNA vehicle. ** P < 0.05 vs NS
siRNA Bg 20 μM
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Fig. 3 Bergapten modulates the expression of proteins involved in autophagy process in MCF-7 and ZR-75 cells. a Western blot analysis of PTEN
(also showed in Fig. 1b) and Beclin1 in MCF-7 cells transfected with non specific (NS) or targeted against PTEN siRNA treated with vehicle (−), Bg
20 μM or Bg 50 μM for 16 h. β-actin was used as loading control. Autoradiographs show the results of one representative experiment. Columns,
are mean of three independent experiments in which band intensities were evaluated in terms of optical density arbitrary units and expressed as
fold change over vehicle, which was assumed to be 1; bars, SD;* P < 0.05 vs NS siRNA vehicle. ^ P < 0.05 vs NS siRNA Bg 20 μM. ** P < 0.05 vs NS
siRNA μM. b Western blot analysis of PI3KIII, UVRAG and AMBRA expression in MCF-7 and ZR-75 cells treated for 16 h with vehicle (−), Bg 20 μM,
Bg 50 μM. Columns, are mean of three independent experiments in which band intensities were evaluated in terms of optical density arbitrary
units and expressed as fold over vehicle, which was assumed to be 1; bars, SD; *P < 0.05 vs vehicle treated cells. c Time course study. Western blot
analysis of p62 and LC3 expression in MCF-7 and ZR-75 cells treated for different times as indicated with vehicle (−), Bg 20 μM, Bg 50 μM.
Autoradiographs show the results of one representative experiment out of three
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which alters LC3-I electrophoretic mobility referred as
LC3-II [14]. Treatment of MCF-7 and ZR-75 cells with Bg
resulted in the conversion of LC3-I to LC3-II after 16 h
which persisted until 24 h under Bg 20 μΜ and not more
evident at 48 h (Fig. 3c). Accordingly, treatment with Bg
for 16 h resulted in a transient decrease in levels of au-
tophagic cargo receptor p62, marker of degradation via
the lysosomes during autophagy.
LC3-GFP, acridine orange assay and transmission electron
microscopy (TEM) revealed formation of autophagosomes
in Bergapten-treated breast cancer cells
We next studied the pattern of subcellular localization of
LC3 which re-localizes from the microtubules to autopha-
gosomal membranes. MCF-7 cells were transiently trans-
fected with an LC3-GFP expression vector and subjected
to fluorescence microscopy. After 16 h treatment, Bg in-
duced LC3-GFP re-localization and concentration into
prototypical autophagic puncta (Fig. 4a).
The autophagic process was also monitored through ac-
ridine orange assay that labels acidic vesicular organelles
(AVOs) bright red. MCF-7 and ZR-75, treated for 16 h
with 20 and 50 μM Bg were stained with acridine orange
and analyzed through FACS. As shown in Fig. 4b in MCF-
7 cells the red fluorescence increased from 0.35 % (con-
trol) to 8.5 % (20 μM Bg) and 44.5 % (50 μM Bg). Analo-
gously, in ZR-75 cells (Fig. 4b) the percentage of red
positive cells increased from 1.42 % (control) to 7.7 %
(20 μM Bg) and 29.2 % (50 μM Bg) respectively indicating
AVO accumulation. To validate the involvement of NF-Y
on autophagic phenotype, MCF-7 cells were treated with
a specific NF-Y siRNA which substantially reduced the
percentage of red positive cells after Bg exposure com-
pared to MCF-7 transfected with NS siRNA (Fig. 4c).
To further investigate the occurrence of a Bg
-dependent autophagic phenotype we used transmis-
sion electron microscopy (TEM). As shown in Fig. 5,
control cells exhibited normal nuclei with uniform
and finely dispersed chromatin, surrounded by cyto-
plasm with normal appearing mitochondria (panels a,
b). 20 μM Bg -treatment for 16 h resulted in the ac-
cumulation of autophagic vacuoles (panels c, d and
e). Particularly, autophagy was clearly evidenced at
50 μM Bg treated for 16 h (panels f, g, h). Similar
results, although in a lesser extent were obtained for
ZR-75 cells (data not shown).
Autophagy favors the inhibition of breast cancer cell
survival after Bergapten stimulus
To comprehend if the autophagic phenotype evoked by
Bg treatment could favor or delay breast cancer cell
death, we analyzed the influence of autophagy on cell
survival after different times of Bg addition. Our results
show that both MCF-7 and ZR-75 cells exposed to Bg
exhibited a significant loss of cell survival (Fig. 6), espe-
cially under Bg 50 μM. Interestingly co-treatment with
the autophagy inhibitor 3-MA effectively counteracted
these inhibitory effects clearly suggesting that autophagy
could early determine the inhibition of cell viability due
to Bg stimulus. Cotreatment with the caspase inhibitor
ZVF was ineffective at 16 h, while it counteracted the Bg
action at 48 h of stimulation, indicating that apoptosis
influences cell viability later respect to autophagy.
We also observed that pre-treatment of MCF-7 cells
with the autophagy inhibitor 3-MA counteracted the ap-
pearance of DNA laddering after 24 h of Bg stimulus
(data not shown).
The results, collectively, evidence that Bg activates the
autophagy which supports the decline of cell survival
through the later occurrence of apoptosis.
Discussion
The importance of the biological function of PTEN rises
from its frequent mutations and deletions in human can-
cer. PTEN governs a plethora of cellular processes in-
cluding survival, proliferation, and energy metabolism,
by suppressing the PI3K/AKT/mTOR pathway [15–17].
Herein, we provided evidences that these molecular sig-
nals may be target of the natural product Bg, a psoralen
compound that belongs to a group of furanocoumarins,
which are found in a variety of fruits and vegetables. On
the basis of our previous data demonstrating that Bg in
breast cancer cells is able to negatively affect the PI3K/
AKT signaling, here we found that this may occur
through PTEN, the main negative regulator of this path-
way. Our study addresses how Bg, by inducing PTEN ex-
pression, produces autophagy in breast cancer cells.
Thus we propose that PTEN might be one of the signal-
ing protein through which Bg acts to affect breast cancer
cell survival.
For instance this emerges from our data showing that
the silencing of this gene was able to abrogate the down-
regulation of p-AKT/p-mTOR triggering autophagic
process under Bg exposure.
It is worth to mention how the lowering of AKT and
mTOR protein levels just rely on the degradative process
of proteins along with autophagy.
We deepen the molecular mechanism through which
Bg might bring to PTEN elevation by performing transi-
ent transfection experiments with different PTEN pro-
moter constructs, showing that the stimulatory effect
induced by Bg on this gene was mediated by a region
containing NF-Y binding site. In fact, site-direct muta-
genesis of this element completely reversed the Bg in-
duced up-regulation of PTEN promoter activity.
Furthermore NF-Y silencing counteracted Bg effects on
PTEN expression.
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Whereas in our previous paper we have shown that
the transcription factor NF-Y mediates Bg action, herein
we further confirmed the crucial role of the activation of
NF-Y, via p38MAPK signaling as the main axis through
which Bg is able to maintain the PTEN promoter trans-
activation as well as mRNA and protein increase. NF-Y
regulates transcription of various genes related to the
cell cycle and various human diseases, as it is required
for the recruitment of RNA polymerase II to permit
transcriptional activation [18].
Besides, recent studies reported that p38-dependent
stress response can drive the autophagy process [19–21].
Interestingly we evidenced the appearance of an authopha-
gic phenotype by Bg treatment as revealed by fluorescence
microscopy of LC3-GFP in breast cancer cells together
with an increase of different key hallmarks of the autopha-
gic process such as Beclin 1, PI3K III, UVRAG and
Ambra1. Moreover our results reveal lipidation of LC3 and
the reduction of p62 along with the activation of autoph-
agy. Both markers further change after 24–48 h of Bg
stimulus addressing the incipient appearance of apoptosis
[8, 9].
Thus the biological outcome of the functional axis
Bg/p38MAPK/NF-Y/PTEN is represented by the ap-
pearance of an early autophagic phenotype which is
crucial for the later inhibition of breast cancer cell
survival since it appears effectively counteracted in
the presence of a specific autophagy inhibitor 3-MA
in both cell types. We retain that Bg induced autoph-
agy represents a preliminary event that pushes breast
cancer cells towards apoptosis as late response, as
evidenced by the effects of the caspase inhibitor ZVF
which counteracted the inhibitory action of Bg on
cell viability but subsequently to 24 h of treatment
[8]. In other words the present paper highlights how,
in a shorter time, Bg triggering autophagy may create
the susceptibility to cell death. For instance, some
types of cancers exhibit autophagic changes after
treatments with irradiation and chemotherapic drugs
[22–26] as adaptative response to protect organisms
during periods of enhanced cellular distress.
Several phytoproducts such as the coumarins, have
shown to inhibit cancer cell proliferation inducing
apoptotic cell death [27, 28]. Furthermore, in vitro
exposure of cancer cells to natural products res-
veratrol and the B-group soya-saponins addresses
autophagic process [29–31] and in the human cer-
vical carcinoma cell line it has been reported that
the furanocoumarin imperatorin, alone or in combin-
ation with cisplatin, is mainly an autophagy inducer
in these cells [32].
Whether autophagy is a death-induced mechanism
or a protective effort for cellular survival is still a
controversy [33, 34]. Most likely, depending on cellu-
lar type, functional status, microenvironment and
therapeutic agents, the persistence over time of au-
tophagy with the increases of cellular self-degradation,
could promote apoptosis.
Conclusions
Thus, on the basis of our data, we can suggest that autoph-
agy precedes cell death demonstrating that p38MAPK/NF-
Y/PTEN represents the signaling pathway driving the ap-
pearance of the morpho-functional features of autophagy
under Bg stimulus. These effects are prevented in the pres-
ence of specific NF-Y siRNA as monitored by flow-
cytometry in MCF-7 cells.
In summary, our results contribute to identify
PTEN as a key target of Bg action in breast cancer
cells for the control of survival and autophagy. PTEN
is transcriptionally regulated by Bg through the in-
volvement of NF-Y transcription factor. Treatment of
cells enhances the expression of Beclin1 and PI3K
III, pivotal factors in the formation of a lipid kinase
complex which in turn allow the recruitment and
shuttling of UVRAG and AMBRA, thus contributing
to the generation of the phagophore. These findings
add further insights on the mechanism of action of
Bg and address how dietary phytochemical com-
pounds may be implemented in the novel strategies
for breast cancer treatment.
Materials and methods
Materials
5-Methoxypsoralen or Bergapten (Bg), aprotinin, leu-
peptin, phenylmethylsulfonyl fluoride (PMFS), sodium
orthovanadate, the known inhibitor of autophagy 3-
Methyladenine (3MA) were purchased from Sigma
Chemical (Milan, Italy). The specific caspases inhibi-
tor Z-VAD-FMK (ZVF) was from R&D Systems
(Milan, Italy). Antibodies used in this study were
from Santa Cruz Biotechnology (Santa Cruz, CA)
(See figure on previous page.)
Fig. 4 Bergapten treatement increases autophagosome formation in MCF-7 and ZR-75 cells. a MCF-7 cells were transiently transfected with
LC3-GFP and treated with vehicle (−) or with Bg 20 μM or Bg 50 μM for 16 h. b MCF-7 and ZR75 cells treated with vehicle (−) or with Bg 20 μM
or Bg 50 μM for 16 h, were incubated with acridine orange and fluorescence was analyzed by flow cytometry. c MCF-7 transfected with non
specific (NS) or targeted against NF-Y siRNA treated with vehicle (−) or with Bg 20 μM for 16 h. Images show the results of one representative
experiment out of three
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except SQSTM1/p62 and PhosphomTOR (Ser2448)
from Cell Signalling (Danvers, MA).
Plasmids
The firefly luciferase reporter plasmid containing the
full-length of the PTEN promoter region pGL3-2768
(−2927/-160) and the different deletion constructs
pGL3-612 (−1389/-778), pGL3-341 (−1118/-778),
pGL3-139 (−916/-778) gifts from Prof. Xi-Liang Zha,
(Shanghai Medical College, Fudan University, Shang-
hai) [12, 13]. The Renilla luciferase expression vector
pRL-TK (Promega, Milan, Italy) was used as a trans-
fection standard. GFP-LC3 Expression Vector #CBA-
401 was from Cell Biolabs, Inc. (San Diego, CA).
Cell culture
Authenticated human breast cancer cells MCF-7 and
ZR75-1 (ZR-75) (American Type Culture Collection-
ATCC) were acquired in 2010, stored according to
supplier’s instructions and used within 4 months
after frozen aliquots resuscitations. Both cell lines
were maintained in DMEM/F-12 medium containing
5 % fetal calf serum (5 %FCS), 1 % L-glutamine, 1 %
Eagle’s nonessential amino acids and 1 mg/ml peni-
cillin/streptomycin in a 5 % CO2 humidified atmos-
phere. Cells were cultured in phenol red-free
DMEM, 0.5 % BSA and 2 mM L-glutamine (serum-
free medium), for 24 h (h) before each experiment.
Bg stimulation was performed in DMEM/F12 con-
taining 5 % charcoal-treated fetal calf serum. MCF-7
cells express endogenous PTEN, while ZR-75 cells
contain a hemizygous deletion of PTEN and a mis-
sense mutation in the other allele [35]. The Bg con-
centrations were chosen on the basis of our previous
studies [8, 9].
Western blotting
Total protein extracts were obtained as previously de-
scribed [36]. Proteins were resolved on a 10 % sodium
dodecyl sulfate–polyacrylamide gel, transferred to a
Fig. 5 Bergapten treatement evokes an autophagic phenotype in MCF-7. TEM analysis, top panels: untreated MCF7 cells (a, b). Bottom panels:
Bg 20 μM (c, d, e) and Bg 50 μM (f, g, H) treated cells. Morphologic findings characteristic of autophagy are enlarged to highlight the
autophagic bodies indicated by the arrows (original magnification: × 10,000). The figure shows the results of one representative experiment
repeated at least three times
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nitrocellulose membrane, probed overnight at 4 °C
with the indicated antibodies. β-actin was used as
loading control.
Reverse transcription and real-time PCR
Cells were treated as indicated and processed as described
[37] The primers were: 5′CCACCACAGCTAGAACTT
ATC3′ (PTEN forward); 5′ATCTGCACGCTCTATA
CTGC3′ (PTEN reverse); 5′-GGCGTCCCCCAACTTC
TTA-3′ (18S forward) and 5′-GGGCATCACAGACCTG
TTATT-3′ (18S reverse).
Transfections and luciferase assays
Transfections were done as previously described [38]
using Fugene 6 reagent (Roche Diagnostics, Milan,
Italy). Luciferase activity was measured with the Dual
Luciferase kit (Promega, Milan, Italy).
Fig. 6 Bergapten treatment reduces cell viability in MCF-7 and ZR-75 cells. MTT assay in MCF-7 and ZR-75 cells treated for 16 h (panel a, b), 24 h
(panel c, d), 48 h (panel e, f) with vehicle (−), Bg 20 μM, Bg 50 μM, or pre-treated for 4 h respectively with 5 mM 3-MA (3-Methiladenine) or
10 μM ZVF (Z-VAD-fmk) as indicated. Columns are mean of three independent experiments and expressed as % over vehicle, which was assumed
to be 100 %; bars, SD; *P < 0.05 vs vehicle. ** P < 0.05 vs Bg 50 μM
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Site-directed mutagenesis
Mutagenesis was performed on pGL3-612 (−1389/-778)
of the PTEN promoter by PCR. The sequence for the
sense primer was: 5′-ACGACCCCATCTCAGCTTagtc
CATCAGTCCTCCACC-3′. The amplified DNA frag-
ment was digested and ligated into pGL3-basic vector.
Mutation was confirmed by DNA sequencing.
Lipid-mediated transfection of siRNA Duplexes
RNA oligonucleotide nonspecific (NS) or directed
against PTEN and NF-Y were purchased from Invitrogen
(Paisley, UK). Cells were transfected using Lipofectamine
2000 reagent (Invitrogen, Paisley, UK) as previously re-
ported [38] according to the manufacturer’s instructions
and then treated as indicated.
MTT assay
Cells (3 × 104 cells/mL) were plated in 24-well plates and
serum-starved for 24 h before the addition of treatment.
The MTT assay was performed as briefly described :
100 μL of MTT (2 mg/mL) (Sigma Aldrich, Milan, Italy)
were added to each well, and the plates were incubated
for 2 h at 37 °C. Then, 500 μL of DMSO were added.
The absorbance was measured with the Ultrospec 2100
Prospectrophotometer (Amersham-Biosciences, Milan,
Italy) at 570 nm.
GFP-LC3 fluorescence
LC3 translocation was detected using the green fluores-
cent protein (GFP)-fused LC3 construct (Cell Biolabs,
Inc. San Diego, CA). Briefly, cells were seeded in 6 well
plates contained glass coverslips and allowed to attach
overnight. 7 μg of LC3-GFP expression plasmid were
transfected using Fugene 6 reagent (Roche Diagnostics,
Milan, Italy). 6 h after transfection, the cells were treated
with vehicle or 20 μΜ or 50 μΜ Bg for 16 h. The cover-
slips with attached cells were stained with the blue-
fluorescent DAPI for nuclear stain. The excess buffer
was removed and the coverslips were mounted. Fluores-
cence analysis was carried out on an OLYMPUS BX51
microscope. Images are representative of three different
experiments.
FACS detection of acidic vesicular organelles
Acidic vesicular organelles (AVOs) were detected and
quantified after vital staining with acridine orange to
monitor autophagic phenotype [24]. Following treat-
ment, cells were stained with 0.5 μg/ml acridine orange
for 15 min at 37 °C. Cells were then trypsinized and col-
lected in phenol-red free medium. Green (510–530 nm)
and red (>650 nm) fluorescence emission from cells was
measured with a Fluorescence Activated Cell Sorter
(FACS) using CellQuest software.
Transmission Electron Microscopy (TEM)
TEM was conducted as previously described [39] Cells
were fixed in 3 % glutaraldehyde solution in 0.1 M phos-
phate buffer (pH. 7.4) for 2 h. Then the samples were
post-fixed in osmium tetroxide (3 %), dehydrated in
graded acetone and embedded in Araldite (Fluka, Buchs,
Switzerland). Ultrathin sections were collected on cop-
per grids and contrasted using both lead citrate and ur-
anyl acetate. The grids were examined in a “Zeiss EM
10” electron microscope.
Statistical analysis
Data were analyzed by Student’s t test using the Graph-
Pad Prism 4 software program.
Additional file
Additional file 1: Figure S1. (A) Time course study. Western blot
analysis of p-p38 and p38 expression in MCF-7 and ZR-75 cells treated as
indicated with vehicle (−), Bg 20 μM, Bg 50 μM. Autoradiographs show
the results of one representative experiment out of three. (B) Western
blot analysis of PTEN in MCF-7 treated with vehicle (−), Bg 20 μM and/or
p38MAPK inhibitor SB203580 (SB 10 μM).
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
FDA, SA, MLP design the experiments. SA conception of the project, analysis
of data, revising critically the manuscript. FDA and MLP drafted the
manuscript. CM and CG carried out the siRNA silencing and performed part
of the WB. MS prepared the cell cultures and performed MTT, RT-PCR and
LC3-GFP experiments. IP performed the TEM analysis. LM assisted with WB
and statistical analysis, FG, AN prepared the samples and carried out the
FACS analysis. SA supervised the manuscript and has given the critical
contribution to the experimental study. All authors read and approved the
final manuscript.
Acknowledgments
This work was supported by Progetti di Ricerca di Interesse Nazionale (PRIN),
Ministero Istruzione Universita’ e Ricerca (MIUR) (grant number 20085Y7XT5);
and Associazione Italiana Ricerca sul Cancro (AIRC) (grant number IG11595
and IG15738).
Author details
1Department of Pharmacy, Health and Nutritional Sciences, University of
Calabria, 87036 Arcavacata di Rende, Cosenza, Italy. 2Health Center, University
of Calabria, 87036 Arcavacata di Rende, Cosenza, Italy. 3Department of
Biology, Ecology and Earth Science (Di.B.E.S.T.), University of Calabria, 87036
Arcavacata di Rende, Cosenza, Italy.
Received: 25 September 2014 Accepted: 29 June 2015
References
1. Chang JC, Hilsenbeck SG, Fuqua SA. Genomic approaches in the
management and treatment of breast cancer. Br J Cancer. 2005;92:618–24.
2. Yamada KM, Araki M. Tumor suppressor PTEN: modulator of cell signaling,
growth, migration and apoptosis. J Cell Sci. 2001;114:2375–82.
3. Piekarski J. Should we start routine assessment of expression of PTEN
protein in patients with breast cancer? J Oncol. 2005;55:480–4.
4. Blanco-Aparicio C, Renner O, Leal JF, Carnero A. PTEN, more than the AKT
pathway. Carcinogenesis. 2007;28:1379–86.
5. Lindmo K, Stenmark H. Regulation of membrane traffic by phosphoinositide
3-kinases. J Cell Sci. 2006;119:605–14.
De Amicis et al. Molecular Cancer  (2015) 14:130 Page 11 of 12
6. De Amicis F, Perri A, Vizza D, Russo A, Panno ML, Bonofiglio D, et al.
Epigallocatechin gallate inhibits growth and epithelial-to-mesenchymal
transition in human thyroid carcinoma cell lines. J Cell Physiol.
2013;228:2054–62.
7. De Amicis F, Giordano F, Vivacqua A, Pellegrino M, Panno ML, Tramontano
D, et al. Resveratrol, through NF-Y/p53/Sin3/HDAC1 complex
phosphorylation, inhibits estrogen receptor alpha gene expression via
p38MAPK/CK2 signaling in human breast cancer cells. FASEB J.
2011;25:3695–707.
8. Panno ML, Giordano F, Rizza P, Pellegrino M, Zito D, Giordano C, et al.
Bergapten induces ER depletion in breast cancer cells through
SMAD4-mediated ubiquitination. Breast Cancer Res Treat. 2012;136:443–55.
9. Panno ML, Giordano F, Palma MG, Bartella V, Rago V, Maggiolini M, et al.
Evidence that bergapten, independently of its photoactivation, enhances
p53 gene expression and induces apoptosis in human breast cancer cells.
Curr Cancer Drug Targets. 2009;9:469–81.
10. Xia W, Gooden D, Liu L, Zhao S, Soderblom EJ, Toone EJ, et al.
Photo-activated psoralen binds the ErbB2 catalytic kinase domain, blocking
ErbB2 signaling and triggering tumor cell apoptosis. PLoS One. 2014.
doi:10.1371/journal.pone.0088983.
11. Panno ML, Giordano F, Mastroianni F, Palma MG, Bartella V, Carpino A, et al.
Breast cancer cell survival signal is affected by bergapten combined with an
ultraviolet irradiation. FEBS Lett. 2010;584:2321–6.
12. Han B, Dong Z, Liu Y, Chen Q, Hashimoto K, Zhang JT. Regulation of
constitutive expression of mouse PTEN by the 5′-untranslated region.
Oncogene. 2003;22:5325–37.
13. Ma DZ, Xu Z, Liang YL, Su JM, Li ZX, Zhang W, et al. Down-regulation of
PTEN expression due to loss of promoter activity in human hepatocellular
carcinoma cell lines. World J Gastroenterol. 2005;11:4472–7.
14. Wild P, McEwan DG, Dikic I. The LC3 interactome at a glance. J Cell Sci.
2014;127:3–9.
15. Shi Y, Paluch BE, Wang X, Jiang X. PTEN at a glance. J Cell Sci.
2012;125:4687–92.
16. Ueno T, Sato W, Horie Y, Komatsu M, Tanida I, Yoshida M, et al. Loss of Pten,
a tumor suppressor, causes the strong inhibition of autophagy without
affecting LC3 lipidation. Autophagy. 2008;4:692–700.
17. De Amicis F, Guido C, Santoro M, Lanzino M, Panza S, Avena P, et al. A novel
functional interplay between progesterone receptor –B and PTEN via Akt,
modulates autophagy in breast cancer cells. J Cellular Mol Med. 2014.
doi:10.1111/jcmm.12363.
18. Ly LL, Yoshida H, Yamaguchi M. Nuclear transcription factor Y and its roles in
cellular processes related to human disease. Am J Cancer Res. 2013;3:339–46.
19. Lv XC, Zhou HY. Resveratrol protects H9c2 embryonic rat heart derived cells
from oxidative stress by inducing autophagy: role of p38 mitogen-activated
protein kinase. Can J Physiol Pharmacol. 2012;90:655–62.
20. Zhong W, Zhu H, Sheng F, Tian Y, Zhou J, Chen Y, et al. Activation of the
MAPK11/12/13/14 (p38 MAPK) pathway regulates the transcription of
autophagy genes in response to oxidative stress induced by a novel copper
complex in HeLa cells. Autophagy. 2014;10:1285–300.
21. Cui Q, Tashiro S, Onodera S, Minami M, Ikejima T. Oridonin induced autophagy
in human cervical carcinoma HeLa cells through Ras, JNK, and P38 regulation. J
Pharmacol Sci. 2007;105:317–25.
22. Kanzawa T, Kondo Y, Ito H, Kondo S, Germano I. Induction of autophagic cell
death in malignant glioma cells by arsenic trioxide. Cancer Res.
2003;63:2103–8.
23. Ellington AA, Berhow MA, Singletary KW. Inhibition of Akt signaling and
enhanced ERK1/2 activity are involved in induction of macroautophagy by
triterpenoid B-group soyasaponins in colon cancer cells. Carcinogenesis.
2006;27:298–306.
24. Bilir A, Altinoz MA, Erkan M, Ozmen V, Aydiner A. Autophagy and nuclear
changes in FM3A breast tumor cells after epirubicin, medroxyprogesteroneand
tamoxifen treatment in vitro. Pathobiology. 2001;69:120–6.
25. Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, Kondo S. Role of
autophagy in temozolomide-induced cytotoxicity for malignant glioma cells.
Cell Death Differ. 2004;11:448–57.
26. Paglin S, Hollister T, Delohery T, Hackett N, McMahill M, Sphicas E, et al. A novel
response of cancer cells to radiation involves autophagy and formation of
acidic vesicles. Cancer Res. 2001;61:439–44.
27. Wang Y, Hong C, Zhou C, Xu D, Qu HB. Screening antitumor compounds
psoralen and isopsoralen from Psoralea corylifolia L. seeds. Evid Based
Complement Alternat Med. 2011;2011:363052.
28. Russo M, Spagnuolo C, Tedesco I, Russo GL. Phytochemicals in cancer
prevention and therapy: truth or dare? Toxins. 2010;2:517–51.
29. Opipari Jr AW, Tan L, Boitano AE, Sorenson DR, Aurora A, Liu JR.
Resveratrol-induced autophagocytosis in ovarian cancer cells. Cancer Res.
2004;64:696–703.
30. Ellington AA, Berhow M, Singletary KW. Induction of macroautophagy in
human colon cancer cells by soybean B-group triterpenoid saponins.
Carcinogenesis. 2005;26:159–67.
31. Chen ML, Yi L, Jin X, Liang XY, Zhou Y, Zhang T, et al. Resveratrol attenuates
vascular endothelial inflammation by inducing autophagy through the cAMP
signaling pathway. Autophagy. 2013;9:2033–45.
32. Jakubowicz-Gil J, Paduch R, Ulz Z, Badziul D, Głowniak K, Gawron A. Cell
death in HeLa cells upon imperatorin and cisplatin treatment. Folia
Histochem Cytobiol. 2012;50:381–91.
33. Sui X, Chen R, Wang Z, Huang Z, Kong N, Zhang M, et al. Autophagy and
chemotherapy resistance: a promising therapeutic target for cancer
treatment. Cell Death Dis. 2013. doi:10.1038/cddis.2013.350.
34. Guido C, Panza S, Santoro M, Avena P, Panno ML, Perrotta I, et al. Estrogen
receptor beta (ERβ) produces autophagy and necroptosis in human
seminoma cell line through the binding of the Sp1 on the phosphatase
and tensin homolog deleted from chromosome 10 (PTEN) promoter gene.
Cell Cycle. 2012;11:2911–21.
35. Perren A, Weng LP, Boag AH, Ziebold U, Thakore K, Dahia PL, et al.
Immunohistochemical evidence of loss of PTEN expression in primary
ductal adenocarcinomas of the breast. Am J Pathol. 1999;155:1253–60.
36. Mauro L, Pellegrino M, De Amicis F, Ricchio E, Giordano F, Rizza P, et al.
Evidences that estrogen receptor alpha interferes with adiponectin effects
on breast cancer cell growth. Cell Cycle. 2014;13:553–64.
37. Rizza P, Barone I, Zito D, Giordano F, Lanzino M, De Amicis F, et al. Estrogen
receptor beta as a novel target of androgen receptor action in breast
cancer cell lines. Breast Cancer Res. 2014. doi:10.1186/bcr3619.
38. De Amicis F, Zupo S, Panno ML, Malivindi R, Giordano F, Barone I, et al.
Progesterone receptor B recruits a repressor complex to a half-PRE site of
the estrogen receptor alpha gene promoter. Mol Endocrinol.
2009;23:454–65.
39. Martinet W, Timmermans JP, De Meyer GR. Methods to assess autophagy in
situ-transmission electron microscopy versus immunohistochemistry.
Methods Enzymol. 2014;543:89–114.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
De Amicis et al. Molecular Cancer  (2015) 14:130 Page 12 of 12
